# Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions

> **NCT00775372** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 40 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Clarithromycin 250mg/5mL

## Key facts

- **NCT ID:** NCT00775372
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-10
- **Final completion:** 2005-12
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00775372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00775372, "Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00775372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*